Earnings calls

Zota Health Care concall ledger

Every earnings call for ZOTA — management tone, guidance, KPIs and promise tracking, quarter by quarter.

ZOTA · 5 transcripts · Healthcare · latest Q4 FY26

Q4 FY26Published 25 May 2026Call held 25 May 2026

ZOTA Q4 FY26 Earnings Call Transcript & Analysis

Consolidated Revenue53,865 lakhs+84% YoYConsolidated EBITDA2,597 lakhsConsolidated EBITDA Margin4.82%Consolidated Gross Margin60.28%

Consolidated Revenue (FY26) 53865 lakhs (+84% YoY); Consolidated EBITDA (FY26) 2597 lakhs; Consolidated EBITDA Margin (FY26) 4.82%. Consolidated revenue from operations for FY26 stood at INR 53,865 lakhs, registering a robust Y-o-Y growth of 83.86%.

Read full transcript & analysis

Q3 FY26Published 05 Feb 2026Call held 05 Feb 2026

ZOTA Q3 FY26 Earnings Call Transcript & Analysis

Consolidated Revenue14,295.14 lakhs+98% YoYConsolidated EBITDA127.58 lakhs

Consolidated Revenue 14295.14 lakhs (+98% YoY); Consolidated EBITDA 127.58 lakhs. Consolidated revenue grew 98.2% YoY to INR 14,295.14 lakhs.

Read full transcript & analysis

Q2 FY26Published 28 Oct 2025Call held 28 Oct 2025

ZOTA Q2 FY26 Earnings Call Transcript & Analysis

Consolidated Revenue12,895 lakhs+92% YoYEBITDA796 lakhs

Consolidated Revenue 12895 lakhs (+92% YoY); EBITDA 796 lakhs. Consolidated revenue grew 92% YoY to INR 12,895 lakhs.

Read full transcript & analysis

Q1 FY26Published 11 Aug 2025Call held 11 Aug 2025

ZOTA Q1 FY26 Earnings Call Transcript & Analysis

Revenue from Operations₹103.58 cr+84% YoYConsolidated EBITDA₹4.83 crEBITDA Margin4.7%

Revenue from Operations ₹104 cr (+84% YoY); Consolidated EBITDA ₹5 cr; EBITDA Margin 4.7%. Consolidated revenue from operations grew 84% YoY to INR 103.58 crores.

Read full transcript & analysis

Q4 FY25Published 30 May 2025Call held 30 May 2025

ZOTA Q4 FY25 Earnings Call Transcript & Analysis

Consolidated Revenue₹292.98 cr+62% YoYGross Margin50%

Consolidated Revenue ₹293 cr (+62% YoY); Gross Margin (Q4) 50%. Consolidated revenue grew 62% YoY to ₹292.98 crores in FY25.

Read full transcript & analysis